|Year : 2012 | Volume
| Issue : 2 | Page : 265-268
Combination of intracameral and intrastromal voriconazole in the treatment of recalcitrant Acremonium fungal keratitis
Randa S Haddad, Georges M El-Mollayess
Department of Ophthalmology, American University of Beirut, Beirut, Lebanon
|Date of Web Publication||21-Apr-2012|
Randa S Haddad
American University of Beirut - Medical Center, P.O. Box 11-0236/D27, Beirut
Source of Support: None, Conflict of Interest: None
| Abstract|| |
We present a report of a 28-year-old female with fungal keratitis due to Acremonium that was unresponsive to full medical therapy over 3 weeks. The patient was treated with superficial keratectomy, intrastromal and intracameral voriconazole injections. There was a marked clinical improvement beginning on day 3 post-therapy that was sustained until the last follow-up at 6 months. This is the first case of fungal keratitis due to Acremonium treated by a combination of intrastromal and intracameral voriconazole. This cost-effective treatment modality proved to be significant in impeding the progression of this potentially blinding disease and improving visual prognosis.
Keywords: Acremonium, Fungal keratitis, Intracameral Injection, Intrastromal Injection, Voriconazole
|How to cite this article:|
Haddad RS, El-Mollayess GM. Combination of intracameral and intrastromal voriconazole in the treatment of recalcitrant Acremonium fungal keratitis. Middle East Afr J Ophthalmol 2012;19:265-8
|How to cite this URL:|
Haddad RS, El-Mollayess GM. Combination of intracameral and intrastromal voriconazole in the treatment of recalcitrant Acremonium fungal keratitis. Middle East Afr J Ophthalmol [serial online] 2012 [cited 2021 Oct 21];19:265-8. Available from: http://www.meajo.org/text.asp?2012/19/2/265/95271
| Introduction|| |
Fungal keratitis is a leading cause of monocular blindness worldwide with a reported incidence varying from 6 to 50% and a tendency to significantly increase in tropical climates.  Predisposing factors to the infection include trauma with organic matter, long-term use of broad-spectrum antibiotics and topical steroid, corneal surface disorders, refractive surgery and specific contact lens disinfectant solutions. 
The most common filamentous fungi that cause keratitis are Fusarium and Aspergillus. In this article we report a case of keratomycosis with an unusual organism, Acremonium. Acremonium is a filamentous cosmopolitan fungus mostly isolated from plant debris, soil, and heating ventilation air conditioning systems in building materials. Fungal keratitis due to Acremonium after laser in situ keratomileusis (LASIK) and nonsurgical trauma to the cornea has been previously reported. 
This case report demonstrates the safe use of intrastromal and intracameral voriconazole injections in the treatment of filamentous fungal keratitis.
| Case Report|| |
A 28-year-old female presented 2 weeks after sustaining injury to her right eye by a blow containing dust. A cosmetic contact lens was in place at the time of trauma and was removed a few hours later. At presentation, she had decreased visual acuity (20/100) and a painful red eye. The patient was already treated with topical ciprofloxacin and a combination of tobramycin/dexamethasone eyedrops along with PO amoxicillin. On examination, the patient had a corneal ulcer with +3 conjunctival injection, a large epithelial defect with underlying thick whitish infiltrates and +4 anterior chamber cells. Cornea cultures were sent for microbiological investigation including potassium hydroxide (KOH) wet-mount preparation, Gram stain, and cultures on blood agar, chocolate agar, and Sabouraud's dextrose agar.
The patient was initially treated with fortified vancomycin (50 mg/ml), amikacin (33 mg/ml), and amphotericin B (1 mg/ml). Although the pain decreased, the vision continued to deteriorate to count fingers at 1 m and a corneal melt began. After 5 days, fungal culture contained Acremonium species identified by microscopic and morphological features based on Sabouraud and fungisel agar. Unfortunately, subspeciation of the organism and its antimicrobial sensitivity could not be assessed in our microbiology laboratory.
Oral voriconazole was our first choice for treatment but was declined by the patient due to financial constraint. The patient was advised to begin topical voriconazole 1% hourly and sporanox PO 400 mg QD. Despite maximal medical treatment, the cornea was melting with impending perforation and an anterior chamber hypopyon was rapidly forming [Figure 1]. We believed that the topical treatment was not reaching therapeutic concentrations in the cornea. Hence, we planned superficial therapeutic keratectomy along with intrastromal and intracameral injection of voriconazole (50 μg/0.1 ml) due to the rapidly deteriorating condition and involvement of the anterior chamber. The injection was prepared using the method described by Prakash et al.  Voriconazole (VFEND; Pfizer Inc, NY) is available as 200 mg of white lyophilized powder in a glass vial. It was reconstituted with 19 ml of lactated ringer solution (LR) to obtain 20 ml of clear concentrate containing 10 mg/ml of voriconazole. An aliquot of 1 ml of this solution was diluted with 20 ml of LR to a concentration of (50 μg/0.1 ml). An informed consent was signed by the patient. In the operating room and under aseptic conditions, superficial therapeutic keratectomy was performed and cultures specimens were acquired from the intrastromal bed and from aqueous fluid. Using a 1-ml tuberculin syringe attached to a 30-G needle, 0.07 ml of voriconazole (50 μg/0.1 ml) was injected intrastromally around the area of the ulcer. The amount of hydration of the cornea was used as a guide to assess the area covered. Similarly, 0.05 ml of voriconazole (50 μg/0.1 ml) was injected intracamerally. Corneal cultures were positive for Acremonium species while the culture from the aqueous tap was negative.
Postoperatively, the patient was maintained on topical amphotericin B, voriconazole 1% Q 1 hour and sporanox 400 mg PO QD. Three days postinjection, there was a significant decrease in eyelid edema, ocular pain, hypopyon and the epithelial defect [Figure 2]. Her vision was still HM due to a pupillary inflammatory membrane blocking the visual axis. Six weeks later, her vision improved to CF at 3 m and the epithelial defect continued to resolve with a significant decrease in the cellular infiltrates and complete resolution of the anterior chamber reaction. However, the pupillary membrane remained. Six months later, the vision improved to 20/100 post-dilation with a quiet eye, a thin central corneal scar and marked reduction in corneal vascularization [Figure 3].
| Discussion|| |
Several drugs have been used to treat filamentous fungal corneal ulcers. Natamycin is the most commonly used topical treatment followed by amphotericin. However, resistance to amphotericin B is increasing. , Itraconazole and voriconazole are the most frequently used systemic treatments for filamentous ulcers although the latter is the preferred topical treatment in an ideal world.  Surgical intervention (such as keratoplasty, evisceration, or enucleation) is necessary in 15-27% of patients, due to advanced keratitis, failed medical therapy and progressive thinning with impending perforation. ,
Numerous case reports indicate that voriconazole has been successful when amphotericin B or fluconazole have been unsuccessful, even in cases of drug-resistant fungal keratitis and endophthalmitis. ,, Voriconazole, a second-generation triazole derived from fluconazole, offers broad-spectrum activity against various fungi affecting the eye. It primarily inhibits the cytochrome P450 14-alpha demethylase and 24-methylene dihydrolanasterol demethylation in certain yeasts and filamentous fungi. It has a molecular mass of 349.32 Da that allows good corneal penetration,  and therefore better ocular bioavailability.
Oral voriconazole has good intraocular penetration with therapeutic levels of the drug achieved in aqueous (1.7 μg/mL) and in vitreous (1.5 μg/mL).  However, oral voriconazole is expensive and can cause systemic side effects such as transient visual disturbances, facial erythema, and elevated liver enzymes.  Animal studies demonstrated effectiveness in ocular penetration when administered topically.  In humans, topical voriconazole was shown to have good corneal epithelial penetration requiring minimal need to rescrape the epithelium. , Aqueous voriconazole concentration can reach up to (6.5 μg/mL) after topical use exceeding the level achieved by oral administration.  In a human study, 85-90% of the drug was absorbed into the aqueous humor with topical use compared to 53% oral administration.  To achieve sustained high levels for effective antifungal therapy in corneal keratitis, voriconazole should be topically administered every 30 minutes. 
Intraocular use of voriconazole in treating fungal keratitis is an off-label use. This modality of treatment might be used in severe cases of fungal keratitis where higher intraocular concentration of the drug is warranted to eradicate the organism. The experimental use of intravitreal voriconazole injections in rodents proved to be safe with no electroretinographical or histopathological abnormalities.  The experimental use of intracameral voriconazole in humans showed no toxic effects when the aqueous concentration was (10 μg/mL - 1.5 mg/mL).  Above 1.5 mg/mL there was a dose-dependant reduction in corneal endothelial cells, trabecular meshwork cells, and retinal pigment epithelial cells. 
Intrastromal administration of voriconazole might be a safe and cost-effective method of providing higher concentration of the drug when there is a risk of corneal melt and perforation. Intrastromal injection of (0.05 - 0.1 ml) of voriconazole (50 μg/0.1 ml) aided in the resolution of different fungal infections.  Repeated intrastromal injections of voriconazole (50 μg/0.1 ml) were tolerated with no long-term ocular toxicity noted.  Intrastromal injections of 0.1 ml of voriconazole (25 μg/ml) have also been used to treat Acanthamoeba keratitis with no complications. 
In the current case, after 3 weeks of topical and oral antifungal treatment, there was clinical deterioration of the corneal ulcer and the culture from the corneal scraping taken in the operating room remained positive and grew Acremonium. Several factors might hamper ocular penetration of the drug through topical use including the thickness of the cornea and the pathogen load. This is the first case report in English peer review literature to treat Acremonium species with the combination of intrastromal and intracameral voriconazole. This medical therapy was safe, allowing higher drug bioavailability within the anterior chamber thus controlling the corneal and intraocular infection compared to topical use. However, clinical trials assessing the safety and efficacy of intrastromal and intracameral voriconazole should be considered.
| References|| |
|1.||Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: A global perspective. Bull World Health Organ 2001;79:214-21. |
|2.||Srinivasan M. Fungal keratitis. Curr Opin Ophthalmol 2004;15:321-7. |
|3.||Alfonso JF, Baamonde MB, Santos MJ, Astudillo A, Fernández-Vega L. Acremonium fungal infection in 4 patients after Laser in Situ Keratomileusis. J Cataract Refract Surg 2004;30:262-7. |
|4.||Prakash G, Sharma N, Goel M, Titiyal JS, Vajpayee RB. Evaluation of intrastromal injection of voriconazole as a therapeutic adjunctive for the management of deep recalcitrant fungal keratitis. Am J Ophthalmol 2008;146:56-9. |
|5.||O'Day DM, Head WS, Robinson RD, Clanton JA. Corneal penetration of topical amphotericin B and natamycin. Curr Eye Res 1986;5:877-82. |
|6.||Thomas PA. Mycotic keratitis: An underestimated mycosis. J Med Vet Mycol 1994;32:235-56. |
|7.||Loh AR, Hong K, Lee S, Mannis M, Acharya NR. Practice patterns in the management of fungal corneal ulcers. Cornea 2009;28:856-9. |
|8.||Reddy PS, Satyendran OM, Satapathy M, Kumar HV, Reddy PR. Mycotic keratitis. Indian J Ophthalmol 1972;20:101-8. |
|9.||Bunya VY, Hammersmith KM, Rapuano CJ, Ayres BD, Cohen EJ. Topical and oral voriconazole in the treatment of fungal keratitis. Am J Ophthalmol 2007;143:151-3. |
|10.||Durand ML, Kim IK, D'Amico DJ, Loewenstein JI, Tobin EH, Kieval SJ, et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol 2005;140:552-4. |
|11.||Kramer M, Kramer MR, Blau H, Bishara J, Axer-Siegel R, Weinberger D. Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology 2006;113:1184-6. |
|12.||Chandrasekar PH, Manavathu E. Voriconazole: A second generation triazole. Drugs Today (Barc) 2001;37:135-48. |
|13.||Hariprasad SM, Mieler WF, Holz ER, Gao H, Kim JE, Chi J, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004;122:42-7. |
|14.||Alffenaar JW, van Assen S, de Monchy JG, Uges DR, Kosterink JG, van der Werf TS. Intravenous voriconazole after toxic oral administration. Antimicrob Agents Chemother 2010;54:2741-2. |
|15.||Vorwerk CK, Streit F, Binder L, Tuchen S, Knop C, Behrens-Baumann W. Aqueous humor concentration of voriconazole after topical administration in rabbits. Graefes Arch Clin Exp Ophthalmol 2008;246:1179-83. |
|16.||Thiel MA, Zinkernagel AS, Burhenne J, Kaufmann C, Haefeli WE. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother 2007;51:239-44. |
|17.||Vemulakonda GA, Hariprasad SM, Mieler WF, Prince RA, Shah GK, Van Gelder RN. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch Ophthalmol 2008;126:18-22. |
|18.||Johnson LB, Kauffmann CA. Voriconazole: A new triazole antifungal agent. Clin Infect Dis 2003;36:630-7. |
|19.||Hernández Prats C, Llinares Tello F, Burgos San José A, Selva Otaolaurruchi J, Ordovás Baines JP. Voriconazole in fungal keratitis caused by Scedosporium apiospermum. Ann Pharmacother 2004;38:414-7. |
|20.||Gao H, Pennesi M, Shah K, Qiao X, Hariprasad SM, Mieler WF, et al. Safety of intravitreal voriconazole: Electroretinographic and histopathologic studies. Trans Am Ophthalmol Soc 2003;101:183-9. |
|21.||Kernt M, Kampik A. Intracameral voriconazole: In vitro safety for human ocular cells. Toxicology 2009;258:84-93. |
|22.||Tu EY. Alternaria keratitis: Clinical presentation and resolution with topical fluconazole or intrastromal voriconazole and topical caspofungin. Cornea 2009;28:116-9. |
|23.||Bang S, Edell E, Eghrari AO, Gottsch JD. Treatment with voriconazole in 3 eyes with resistant Acanthamoeba keratitis. Am J Ophthalmol 2010;149:66-9. |
[Figure 1], [Figure 2], [Figure 3]